arrow
Y

Yeşim Aydınok

ege university school of medicine
H指数:31
被引数:4,899

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

阿伐曲泊帕用于儿童持续性及慢性免疫性血小板减少症:一项3b期临床试验中关于应答临床特征的回顾性分析

2026-08-210
PREAI
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia

II期a随机研究评估萨帕鲁森在非输血依赖性β-地中海贫血中间型患者中的应用

2026-06-080
OAAI
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trial

一项关于使用氨脲嘧啶/谷胱甘肽途径病原体灭活血红蛋白红细胞预防寨卡病毒输血传播感染的随机、双盲、对照、平行组研究(RedeS研究)——一项III期临床试验方案

2026-05-010
PRE
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial

米塔吡范(mitapivat)用于非输血依赖性α-地中海贫血或β-地中海贫血成人患者的治疗(ENERGIZE):一项III期、国际、随机、双盲、安慰剂对照试验

2025-06-190
PRE
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study

avatrombopag用于治疗儿童和青少年免疫性血小板减少症(AVA-PED-301):一项多中心、随机、双盲、安慰剂对照、Ⅲb期研究

2025-05-230
PRE
Thalassaemia
LANCET
IF88.5
2022-06-01116
PRE
Recommendations for Pregnancy in Rare Inherited Anemias

罕见遗传性贫血的妊娠建议

2020-08-128
OAAI
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

Luspatercept在输血依赖性 β-地中海贫血患者中的3期试验

2020-03-26209
OAAI